 SOUTH SAN FRANCISCO, Calif., March 17, 2022 GLOBE NEWSWIRE -- CytomX Therapeutics, Inc. Nasdaq: CTMX, a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data supporting the ongoing development of its conditionally activated cytokine program will be presented at the American Association for Cancer Research AACR Annual Meeting on April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. 